Monopar Therapeutics Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report; separate Q4 financial results are not clearly provided in the filing text.
Business context
Monopar is a clinical-stage biopharmaceutical company developing oncology therapeutics. It had no approved products and generated no product revenue. Its programs were Validive, camsirubicin, MNPR-101 radiopharmaceuticals and imaging agent, and preclinical-stage MNPR-202.
Key financial results
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | None | None | No commercial product revenue |
| Research and development expense | $7.59 million | $6.49 million | Up $1.10 million |
| General and administrative expense | $2.95 million | $2.63 million | Up $0.31 million |
| Total operating expenses / operating loss | $10.54 million | $9.13 million | Loss increased $1.41 million |
| Net loss | $10.52 million | $9.10 million | Loss increased $1.41 million |
| Basic and diluted loss per share | $0.83 | $0.73 | Loss per share increased |
| Net cash used in operating activities | $7.23 million | $7.32 million | Approximately flat |
Gross margin and operating margin are not meaningful because the company had no revenue. Interest income was $21,000, versus $24,000 in 2021.
Liquidity and capital
- At December 31, 2022, cash and cash equivalents were $8.19 million and investments were $4.93 million, totaling approximately $13.12 million in cash and liquid investments.
- Current liabilities were $3.13 million; total liabilities were $3.14 million. The balance sheet reports no debt.
- Management stated that funds available as of March 10, 2023 were expected to fund planned operations at least through March 31, 2024. Management reported no substantial doubt about the company’s ability to continue as a going concern, while emphasizing the need for additional funding to advance programs.
- Operating cash use was $7.23 million. The $12.12 million decline in cash and cash equivalents includes $4.92 million used to purchase Treasury investments; it should not be read as operating burn alone.
- 2022 ATM sales generated $87,000 net of fees and expenses. From January 1 through March 10, 2023, the company sold 241,475 shares for approximately $837,000 net of commissions.
Material changes and program updates
- R&D expense rose primarily with Validive and camsirubicin trial execution and manufacturing. Lower R&D personnel costs partly offset the increase. G&A growth was principally personnel and stock-based compensation.
- Validive’s Phase 2b enrollment in the global VOICE Phase 2b/3 trial was completed in 2022, and Phase 3 enrollment began. An independent data monitoring committee’s interim go/no-go decision was expected by the end of March 2023; the filing did not report the outcome.
- Camsirubicin’s Phase 1b dose-escalation trial was enrolling at dose level five, 650 mg/m², more than twice the highest dose in prior trials. The company reported no drug-related cardiotoxicity to date at the current dose level. Topline results were anticipated by year-end 2023, subject to possible delay if dose escalation continued.
- For MNPR-101-Zr, preclinical imaging results prompted Monopar and NorthStar to commit additional funding with the aim of starting a first-in-human imaging study as early as year-end 2023. MNPR-202 remained in preclinical development with a collaborator.
Outlook, risks and contingencies
- The company expected to seek significant additional capital or a suitable partner within 12 months. Completing the VOICE program, including a possible second confirmatory Phase 3 trial, was estimated to require funding in the millions or tens of millions of dollars, depending on partnership arrangements. Without funding or a partner, Monopar said it might delay or discontinue programs.
- Key risks include a negative Validive interim decision or unsuccessful trials; reliance on third-party manufacturers, research organizations and clinical sites; patient enrollment and regulatory delays; and the possibility that candidates never receive approval or generate revenue.
- Management also cited inflation, supply-chain and shipping costs, Russia-Ukraine-related disruption, continuing COVID-19 uncertainty, volatile financial markets and difficulty raising capital. These could increase costs, delay development or constrain financing.
- Validive’s Onxeo license includes up to $108 million in potential milestones and 5%–10% royalties on net sales. No milestones were met and no additional payments beyond the original $1 million license fee were due as of the filing.
- No material adverse legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements; management concluded internal control over financial reporting and disclosure controls were effective.
Important facts for investors to verify
- Whether the Validive interim analysis supported continuing the VOICE Phase 3 program, and the resulting enrollment, funding and regulatory plan.
- Current cash, investment balances, operating burn and financing activity compared with management’s stated runway through March 31, 2024.
- Whether Monopar secured a Validive partner or additional financing, and the dilution or other terms involved.
- Updated camsirubicin safety, dose-escalation and topline timing; confirmatory evidence will be needed beyond early-stage findings.
- Progress, funding commitments and trial timelines for MNPR-101-Zr, MNPR-101 radiotherapeutics and MNPR-202.